A Phase 2 interventional study of irinotecan in Small Cell Lung Cancer, sponsored by Guangdong Association of Clinical Trials. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-03.
Sponsored by Guangdong Association of Clinical Trials · Phase 2, Interventional, and Treatment
The purpose of this study is to identify the appropriate dose of irinotecan by dose escalation(dose climbing) test. The study would provide rationale for regimen decision in a future phase III clinical trial, in which irinotecan combined with cisplatin(IP) will be selected as therapeutic drugs.
To determine the Maximum Tolerated Dose (MTD) and Limiting Toxicity (DLTs) of irinotecan in patients with extensive stage small cell lung cancer treated with irinotecan plus cisplatin
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's planned enrollment of 54 is close to the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Guangdong Association of Clinical Trials is the lead sponsor of 53 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Marrow,kidney, liver,heart and lung are well -functioning,and absolute count of
Exclusion Criteria:
irinotecan; 60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
Drug: irinotecan
60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
Limiting Toxicity (DLT )in the irinotecan
Time frame: up to 18 weeks
Maximum Tolerated Dose(MTD)in the irinotecan
Time frame: up to 18weeks
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guangdong Association of Clinical Trials